Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on June 7, 2016. The filing serves to disclose a presentation used by management at investor conferences and meetings.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a presentation exhibit rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document solely references the attachment of a company presentation dated June 2016.
Guidance, Outlook, and Risks
- Regulation FD Disclosure: The filing includes a presentation (Exhibit 99.1) used for investor communications.
- Legal Status: The information in the presentation is explicitly not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference unless specifically cited in another filing.
- Outlook: Specific guidance or outlook details are contained within the attached presentation, which is not included in the provided text.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Company presentation dated June 2016) for actual business updates, as the 8-K text only references its existence.
- Confirm that the presentation materials are not legally binding or "filed" under the Exchange Act unless explicitly referenced elsewhere.
- Note the discrepancy between the request metadata ("HARROW, INC.") and the actual registrant name in the filing ("IMPRIMIS PHARMACEUTICALS, INC.").